Indivior Pharmaceuticals, Inc. (INDV) intrinsic value & 10-year financials
Indivior Pharmaceuticals, Inc. (INDV) has a Graham intrinsic value of $23.06 per share. At $32.45 on Oct 17, 2026, the stock trades 41% above that value. Over the last 7 fiscal years revenue grew 11.9% a year to $1.2B, with an average return on invested capital of -34.4%.
- Graham intrinsic value
- $23.06
- Share price (Oct 17, 2026)
- $32.45
- Price vs Graham value
- 41% above
- Market cap
- $4.2B
- Revenue (FY2025)
- $1.2B
- Revenue growth (7-yr CAGR)
- 11.9%
- ROIC (10-yr avg)
- -34.4%
- Free cash flow (FY2025)
- -$93.0M
INDV 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $1.2B | $210.0M | $1.64 | -$93.0M | 21.1% | -181.3% |
| FY2024 | $1.2B | $2.0M | $0.02 | $7.0M | 2.7% | -6.4% |
| FY2023 | $1.1B | -$129.0M | -$0.94 | -$308.0M | -14.3% | 40.6% |
| FY2022 | $901.0M | -$44.0M | -$0.32 | -$9.0M | -9.0% | 7.1% |
| FY2021 | $791.0M | $205.0M | — | $349.0M | 26.9% | -32.0% |
| FY2020 | — | — | — | — | — | — |
| FY2014 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Indivior Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Indivior Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just 1.5% ROIC.
Indivior Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Indivior Pharmaceuticals, Inc. is modeled at 3.9% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $23.06 per share.